Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs BAT in Polycythemia Vera (RESPONSE-2)
NCT02038036Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of ruxolitinib in polycythemia vera (PV), sponsored by Novartis. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT02038036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038036.